DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20150261

Assessment of hearing loss in multi-drug resistant tuberculosis (MDR-TB) patients undergoing Aminoglycoside treatment

Sheikh Nizamuddin, Farhan Ahmad Khan, Abdur Rehman Khan, Chand Miyan Kamaal

Abstract


Background: Incomplete treatments and treatment failures has led to Multi-drug resistant tuberculosis, which has emerged as a significant problem in treating tuberculosis and thus the second line drugs are used with the concomitant increase in the incidence of adverse effects.

Methods: This prospective study was carried out from June 2009 to May 2014 in the department of ENT in collaboration with TB & Chest at Teerthanker Mahaveer Medical College & Research Centre.

Out of 104, only 84 patients were included in our study. Patients were divided into three groups: group I (n=27) patients using Amikacin, group II (n=40) patients using kanamycin and group III (n=17) patients using streptomycin. Baseline pre-treatment pure tone audiometry was performed on all the patients and repeated every three months until completion of therapy.

Results: Patients included were 15 to 55 years age with higher number of males (65%, n=55) than females (35%, n =29). Only 22.7% (n=19) of patients were found to be suffered from Hearing Loss. At the end of the study (at 12 month), Overall incidence of HFL was 58.0% (n=11) while incidence of Dead ear was 31.5% (n=6) and LFL was 10.5% (n=2). Amikacin was found to be more Ototoxic than Kanamycin and streptomycin.

Conclusion: Aminoglycosides in MDR-TB patients may cause irreversible hearing loss involving higher frequencies and can become a hearing handicap as speech frequencies are too implied in more or less of the patients, thus underlining the need for regular audiologic evaluation in patients of MDR-TB during the treatment.

 


Keywords


Tuberculosis, MDR-TB, Amikacin, Kanamycin, Streptomycin

Full Text:

PDF

References


"Global Tuberculosis Control 2014, WHO, Geneva, 2014 www.who.int/tb/publications/global_report.

TB India 2012 Revised National TB Control Programme Annual Status Report, New Delhi, 2012 www.tbcindia.nic.in/documents.html.

Sharma SK, Alladi M. Multidrug resistant T B: a menace that threatens to destabilize tuberculosis control. Chest. 2006;130:261-72.

Drobniewski FA, Balabanova YM. The diagnosis and management of multiple-drug-resistant tuberculosis at the beginning of the new millennium. Int J Infec Dis. 2002,6:S21-31.

Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ. 2002,325:1282-6.

Peloquin CA. Pharmacology of the antimicrobial drugs. Med Clin North Am. 1993,77(6):1253-62.

Guidelines for management of drug resistant tuberculosis WHO/TB/Geneva; 2006:361.

de Jager P, van Altena R. Hearing loss and nephrotoxicity in long term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002,6(7):622-7.

Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119-26.

Huizing EG, deGroot JCMJ. Human cochlear pathology in aminoglycoside ototoxicity: a review. Acta Otolaryngl Suppl (Stockh). 1987,436:117.

American Speech-Language-Hearing Association audiologic management of individuals receiving cochleotoxic drug therapy. Guidelines for audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994;34(12):11-9.

Ormerod LP. Multidrug resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull. 2005;73–74:17-24.

Rougier F, Claude D, Maurin M, Maire P: Aminoglycoside nephrotoxicity. Curr Drug Targets Infect Disord. 2004,4(2):155-62.

Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear, Nose and Throat Disorders. 2007;7:5.

Powell SH, Thompson WL, Luthe MA. Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. Journal of Infectious Diseases. 1983;147:918–32.

Tablan OC, Reyes MP, Rintelmann WF, Lerner AM. Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis. Journal of Infectious Diseases. 1984;149:257–63.

Dreschler WA, van der Hulst RJ, Tange RA, Urbanus NA. Role of high-frequency audiometry in the early detection of ototoxicity: II. Clinical aspects. Audiology. 1989;28:211–20.

Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, et al. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. Journal of Infectious Diseases. 1992;165:1026–32.

Campbell Kathleen CM. Audiologic monitoring

for ototoxicity. In Ototoxicity. Edited by Roland P, Rutka J. B C Decker publishers; 2004; 153-160.

Fausti SA, Helt WJ, Gordon JS, Reavis KM, Philips DS, Konard Martin DL. Audiologic monitoring for ototoxicity and patient management. In Pharmacology and ototoxicity for audiologists. Edited by KCM Campbell. New York: Thomson Delmar Learning; 2007.

Matz GJ. Aminoglycoside cochlear toxicity. Otolaryngol Clin North Am. 1993;26(5):705-12.

Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al,. Adverse events in the treatment of multidrug resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8(11):1382-4.

Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, et al,. Occurrence of serious adverse effects in patients receiving community based therapy for multidrug resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5(7):648-55.

Fausti SA, Rappaport BZ, Schechter MA, Frey RH, Ward TT, Brummett RE. Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies. Am J Otolaryngol. 1984;5(3):177-82.

Campbell KC, Meech RP, Klemens JJ, Gerberi MT, Dysstad SS, Larsen DL, et al. Prevention of noise- and drug induced hearing loss with D-methionine. Hear Res. 2007;226(1–2):92-103.